Promising · 6.8/10
Rapamycin
Rapamycin (sirolimus) inhibits mTORC1, a nutrient-sensing pathway tied to autophagy, senescence signaling, immune aging, and lifespan in animals. The animal evidence is unusually strong: Harrison 2009 and Miller 2014 showed lifespan extension in the NIA Interventions Testing Program. Human longevity evidence is still early. Moel 2025 found one year of weekly low-dose rapamycin was relatively safe in healthy aging adults, but the primary visceral-fat endpoint was not meaningfully improved. Read the full breakdown →
The prediction game
Where does Rapamycin go in 12 months?
Lock a call and say how sure you are. Right and confident earns the most; a leaderboard spot is the prize. No money, no stakes.
The Crowd’s Call
Rising or fading over the next 12 months? Lock your call and find out if you saw it coming.
Be the first scout on record for Rapamycin. Permanent credit on this page, plus points when your call resolves.
One call per intervention. It locks the moment you submit (no edits, no cancels) and resolves in 12 months. See the scout leaderboard →
Weigh In
Your input feeds the community signal shown beside my verdict. It informs the board and it never sets the score by itself. How community input works.
Same as above — one verification covers all your entries here.
For education only, not medical advice. Supplements, peptides, and protocols can interact with medications and conditions. Talk to a qualified clinician before starting anything here.